Initial ACEI/ARB Dosing for eGFR 44
Start with standard initial doses of ACEI or ARB without dose reduction, as an eGFR of 44 mL/min/1.73 m² (CKD stage G3b) does not require initial dose adjustment for most agents. 1
Dosing Strategy
With an eGFR of 44, you are dealing with moderate CKD (stage G3b), which allows for:
- Standard starting doses for most ACEIs and ARBs
- Titration to maximum tolerated doses as recommended by guidelines, since the proven cardiovascular and renal benefits were achieved in trials using these higher doses 1
The key principle from KDIGO 2024 guidelines is that RAS inhibitors should be administered at the highest approved dose that is tolerated to achieve maximum benefit 1. This means you should not be conservative with dosing simply because of the eGFR level.
Specific Dosing Considerations
Agent Selection Based on Renal Excretion:
- Preferred agents at this eGFR include those with dual hepatic/renal elimination or primarily hepatic metabolism (e.g., fosinopril, telmisartan)
- Renally-excreted agents may require dose adjustment only at lower eGFRs (typically <30 mL/min/1.73 m²) 2
Initial Dosing Examples:
- Lisinopril: Start 5-10 mg daily (standard initial dose)
- Enalapril: Start 2.5-5 mg daily (standard initial dose)
- Losartan: Start 25-50 mg daily (standard initial dose)
- Telmisartan: Start 40 mg daily (standard initial dose)
Monitoring Protocol
Critical monitoring timeline 1:
- Check BP, serum creatinine, and potassium within 2-4 weeks of initiation
- Accept creatinine increases up to 30% within 4 weeks—this reflects beneficial hemodynamic changes reducing glomerular hyperfiltration 3
- Continue therapy unless creatinine rises >30% or significant hyperkalemia develops 1
Common Pitfalls to Avoid
Do not stop therapy for eGFR dips <30%: The initial eGFR decline with RAS inhibitors is hemodynamically mediated, reversible, and actually predicts greater long-term kidney protection 3
Do not underdose: Starting with unnecessarily low doses or failing to titrate up defeats the purpose, as benefits are dose-dependent 1
Do not discontinue at eGFR <30: Guidelines explicitly recommend continuing ACEIs/ARBs even when eGFR falls below 30 mL/min/1.73 m² 1
Manage hyperkalemia medically first: Use potassium-lowering strategies rather than immediately reducing or stopping the RAS inhibitor 1
Titration Strategy
After confirming tolerability at 2-4 weeks:
- Uptitrate to target doses used in landmark trials
- For lisinopril: target 20-40 mg daily
- For losartan: target 100 mg daily
- For telmisartan: target 80 mg daily
Twice-daily dosing should be considered for intermediate-acting agents when using higher doses 2.
Absolute Contraindications to Continuation
Only reduce dose or discontinue if 1:
- Creatinine increase >30% within 4 weeks
- Symptomatic hypotension unresponsive to management
- Uncontrolled hyperkalemia despite medical treatment
- Uremic symptoms with eGFR <15 mL/min/1.73 m²